Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.50.

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research reaffirmed a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday, June 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th.

Evolus Stock Down 0.4%

NASDAQ EOLS traded down $0.03 during trading on Friday, hitting $7.98. The stock had a trading volume of 60,692 shares, compared to its average volume of 1,025,750. The company has a market capitalization of $526.88 million, a PE ratio of -15.34 and a beta of 1.42. The firm has a 50 day moving average price of $7.51 and a 200 day moving average price of $6.34. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 105,108 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the sale, the insider owned 499,592 shares in the company, valued at $4,516,311.68. This represents a 17.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC purchased a new position in Evolus in the second quarter worth approximately $71,000. WINTON GROUP Ltd acquired a new position in Evolus during the 2nd quarter worth approximately $77,000. Squarepoint Ops LLC increased its position in shares of Evolus by 24.8% in the 2nd quarter. Squarepoint Ops LLC now owns 197,708 shares of the company’s stock valued at $1,372,000 after purchasing an additional 39,316 shares during the last quarter. Angeles Wealth Management LLC purchased a new stake in shares of Evolus in the 2nd quarter valued at approximately $732,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of Evolus in the 2nd quarter valued at $193,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a medical aesthetics company focused on developing and commercializing products for healthcare professionals and consumers. The company’s business is centered on aesthetic treatments designed to address facial lines, wrinkles, skin quality and other signs of aging.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines.” The company markets Jeuveau through its physician-focused Evolus Aesthetic Center platform and related digital tools, education and patient-engagement services.

The company has expanded beyond neuromodulators into dermal fillers and other aesthetic products, including its Evolysse hyaluronic acid filler portfolio.